Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents

Inclusion Criteria: To be considered eligible for enrollment, an individual must meet the criteria listed below. * Age 13 years and 0 days to 24 years and 364 days at the time of consent * Confirmed or suspected to have acquired HIV infection at age 10 years or older * HIV-1 infection as documented by any FDA-approved ELISA test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, HIV-1 DNA, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA at any time prior to pre-entry * Absolute CD4 T-cell count greater than 350 cells/ul at pre-entry * Cohort 1 - Not receiving ART and no exposure to ART in the 24 weeks prior to pre-entry: Quantitative HIV-1 plasma RNA (viral load) less than 50,000 copies/ml on two consecutive determinations at least 8 weeks apart in the 24 weeks prior to and including pre-entry * Cohort 2 - Currently receiving ART and received ART for at least the 24 weeks prior to pre-entry: Quantitative HIV-1 plasma RNA (viral load) less than 400 copies/ml on two consecutive determinations at least 8 weeks apart in the 24 weeks prior to and including pre-entry * Willingness to refrain from regular use of foods/supplements containing probiotics other than that supplied by the study during the course of study participation Exclusion Criteria: To be considered eligible for enrollment, an individual must not meet any of the criteria listed below. * Known hypersensitivity to probiotics * Active AIDS-defining condition or acute serious illness * Cohort 1 - Not receiving ART and no exposure to ART in the 24 weeks prior to pre-entry: Any quantitative HIV-1 plasma RNA (viral load) equal to or greater than 50,000 copies/ml during the 24 weeks prior or at pre-entry. * Cohort 2 - Currently receiving ART and received ART for at least the 24 weeks prior to pre-entry: Any quantitative HIV-1 plasma RNA (viral load) equal to or greater than 400 copies/ml during the 24 weeks prior or at pre-entry * Known history of inflammatory bowel disease or similar disorder of the GI tract * Current treatment with immune-modulating or immune-suppressive therapy * Active malignancy at pre-entry * Pregnancy * Grade 3 or higher clinical or laboratory toxicities at the time of randomization * Regular use of foods or supplements containing probiotics within the 2 weeks prior to randomization (see Appendix V) * Concurrent participation in the ATN 061, 071, 081, and/or 101 protocols